US Bancorp’s ADMA Biologics ADMA Stock Holding History

US Bancorp’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8K	Buy	1,887 +1,312	+228%	+$12K	﹤0.01%	3293
2026 Q1	$5.18K	Buy	575 +67	+13%	+$1.06K	﹤0.01%	3558
2025 Q4	$9.27K	Buy	508 +87	+21%	+$1.47K	﹤0.01%	3358
2025 Q3	$6.17K	Sell	421 -90	-18%	-$1.54K	﹤0.01%	3469
2025 Q2	$9.3K	Sell	511 -24	-4%	-$489	﹤0.01%	3451
2025 Q1	$10.6K	Buy	535 +96	+22%	+$1.66K	﹤0.01%	3413
2024 Q4	$7.53K	Buy	439 +18	+4%	+$339	﹤0.01%	3524
2024 Q3	$8.42K	Hold	421	–	–	﹤0.01%	3422
2024 Q2	$4.71K	Hold	421	–	–	﹤0.01%	3533
2024 Q1	$2.78K	Buy	+421	New	+$2.3K	﹤0.01%	3661
2023 Q1	–	Sell	-287	Closed	-$1.11K	–	4078
2022 Q4	$1.11K	Buy	+287	New	+$885	﹤0.01%	3904
2021 Q2	–	Sell	-29,751	Closed	-$52K	–	3983
2021 Q1	$52K	Buy	+29,751	New	+$68.1K	﹤0.01%	2560
2020 Q2	–	Sell	-1,009	Closed	-$3K	–	3711
2020 Q1	$3K	Buy	+1,009	New	+$3.49K	﹤0.01%	3351
2015 Q1	–	Sell	-2,000	Closed	-$22K	–	3548
2014 Q4	$22K	Buy	+2,000	New	+$22.9K	﹤0.01%	2851

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

US Bancorp's ADMA Position: Q2 2026 in Review

US Bancorp increased its ADMA Biologics (ADMA) stake by 228% in Q2 2026, buying an estimated $12K and bringing the position to 1,887 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3293.

US Bancorp first reported a position in ADMA in Q4 2014 and has held it in 14 quarters since. The position peaked at $52K in Q1 2021. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

US Bancorp held 1,887 shares of ADMA Biologics worth $15.8K as of Q2 2026.
US Bancorp bought 1,312 ADMA Biologics shares in Q2 2026, an estimated $12K.
ADMA Biologics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3293 holding.
US Bancorp first reported a position in ADMA Biologics in Q4 2014 and has held it in 14 quarters since.
US Bancorp's ADMA Biologics position peaked at $52K in Q1 2021.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.